The Relationship Between Serum Endocan and ADMA Levels and Penile Doppler Ultrasonography in Erectile Dysfunction
July 28, 2023 updated by: Cagri Akpinar, Ankara Etlik City Hospital
The Relationship Between Serum Endocan and ADMA Levels and Penile Doppler Ultrasonography Findings in Patients With Vasculogenic Erectile Dysfunction
The gold standard diagnosis in patients admitted to the hospital with the complaint of erectile dysfunction is penile doppler ultrasonography.
This procedure is an invasive procedure and can cause various complications.
Therefore, in this study, we aimed to support and define the diagnosis of erectile dysfunction with some biomarkers that can be measured in blood samples.
At this point, we performed penile doppler ultrasonography, which is the gold standard test, for all patients who applied with the complaint of erectile dysfunction, and compared the results of penile doppler and serum biomarkers in the patients.
Study Overview
Status
Completed
Study Type
Observational
Enrollment (Actual)
73
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Ankara, Turkey, 06800
- Ankara City Hospital Bilkent
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
N/A
Sampling Method
Non-Probability Sample
Study Population
tertiary care clinic
Description
Inclusion Criteria:
- Patients with severe erectile dysfunction according to International Index of Erectile Function-15 questionnaire
- Patients who have not received medical or surgical treatment before
- Patients without comorbidity and related drug use
Exclusion Criteria:
- Patients who have had previous pelvic trauma or surgery,
- Patients who have benefited from using phosphodiesterase-5 enzyme inhibitors,
- Patients with psychogenic erectile dysfunction and moderate or mild erectile dysfunction according to International Index of Erectile Function-15 questionnaire,
- Patients who have neurological disease, chronic liver disease and patients with chronic renal failure and those who used drugs that could cause erectile dysfunction
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To evaluate the relationship between serum endocan (endothelial cell-specific molecule-1), ADMA (asymmetric dimethylarginine) values and penile Doppler ultrasonography findings in patients with severe Erectile dysfunction.
Time Frame: 10 days from the outpatient clinic admission
|
10 days from the outpatient clinic admission
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 17, 2017
Primary Completion (Actual)
January 20, 2020
Study Completion (Actual)
June 12, 2020
Study Registration Dates
First Submitted
July 28, 2023
First Submitted That Met QC Criteria
July 28, 2023
First Posted (Actual)
August 7, 2023
Study Record Updates
Last Update Posted (Actual)
August 7, 2023
Last Update Submitted That Met QC Criteria
July 28, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- E-18-23-52
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.